The clinical guidelines and protocols for the practice of emergency medicine presented in this document are designed to be a useful resource not only for those wishing to become emergency medicine specialists, but also for general practitioners and other healthcare providers tasked with caring for p...atients in hospital emergency departments. Healthcare providers using this Emergency Medicine Clinical Guideline (EMCG) are provided with fundamental concepts and principles essential to emergency medicine and the management of patients with undifferentiated emergency conditions.
more
Rwanda Guidelines for variation to registered pharmaceutical products.
Available in german, arabic, english, greek, croatian, kurdish, italian, polish, portugüse, russian, spanish, turkish, vietnamese
https://www.migration-gesundheit.bund.de/de/gesundheit-und-vorsorge/fraüngesundheit/
Section I
Somatoform disorders
Child Psychiatry and Pediatrics
Chapter I.1
Supplement Article
Antiretrovirals to Prevent HIV Infection • CID 2015:60 (Suppl 3) • S159 - S160
Временные рекомендации4 ноября 2020 г.
В данной редакции документа представлены обновленные рекомендации в таблице, посвященной важнейшим мерам по подготовке, обес...печению готовности и реагированию в связи с COVID-19 при различных сценариях передачи инфекции,
а также приводится обновленный полный перечень технических руководящих указаний ВОЗ по COVID-19.
(measures to prepare and provide readiness and a response plan for COVID-19)
more
This document is updated.
Please check the document:Priority medical devices list for the COVID-19 response and associated technical specifications
Practical guide for doctors, nurses,laboratory technicians, medical auxiliaries,water and sanitation specialists and logisticians
Временное руководство23 декабря 2020 г.
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more